Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Cash from Investing Activities (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Cash from Investing Activities for 8 consecutive years, with $88000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Investing Activities changed N/A year-over-year to $88000.0, compared with a TTM value of -$230000.0 through Dec 2025, up 64.51%, and an annual FY2025 reading of -$230000.0, up 64.51% over the prior year.
  • Cash from Investing Activities was $88000.0 for Q4 2025 at Arcturus Therapeutics Holdings, up from -$181000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $378000.0 in Q2 2022 and bottomed at -$3.8 million in Q4 2022.
  • Average Cash from Investing Activities over 5 years is -$828388.9, with a median of -$379000.0 recorded in 2021.
  • Peak annual rise in Cash from Investing Activities hit 193.56% in 2022, while the deepest fall reached 1688.98% in 2022.
  • Year by year, Cash from Investing Activities stood at -$1.1 million in 2021, then tumbled by 240.52% to -$3.8 million in 2022, then soared by 77.02% to -$875000.0 in 2023, then surged by 90.86% to -$80000.0 in 2024, then surged by 210.0% to $88000.0 in 2025.
  • Business Quant data shows Cash from Investing Activities for ARCT at $88000.0 in Q4 2025, -$181000.0 in Q3 2025, and -$137000.0 in Q1 2025.